amineptine / Generic mfg. - LARVOL DELTA

Intrahospital dissemination of multidrug-resistant Acinetobacter baumannii at a teaching hospital in Northeast of Mexico. (PubMed, Infect Prev Pract) - "Among ST detected (ST1694, ST758, ST124, and ST490), ST124, which belongs to the high-risk CC636 clonal complex, is reported for the first time in Mexico...High antimicrobial resistance, such as MDR and DTR, were observed in this hospital. DTR surveillance and early recognition of MDR A. baumannii clones should be performed routinely to prevent their dissemination."

Journal • Infectious Disease

Challenges in the treatment of dysthymia: a narrative review. (PubMed, Expert Rev Neurother) - "Within the realm of dysthymia treatment, several antidepressants, including imipramine, sertraline, paroxetine, minaprine, moclobemide, and amineptine, in addition to the antipsychotic agent amisulpride, have demonstrated superiority over placebo. However, these findings remain inconclusive due to the limited number of studies and substantial methodological limitations prevalent in a significant proportion of them. Limitations include factors like small sample sizes, the absence of placebo comparisons, and a lack of study blinding."

Journal • Review • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

Pharmacological treatment for methamphetamine withdrawal: A systematic review and meta-analysis of randomised controlled trials. (PubMed, Drug Alcohol Rev) - "There is insufficient evidence to indicate any medication is effective for the treatment of methamphetamine withdrawal. The poor quality of the evidence indicates a need for better powered, high-quality trials."

Journal • Retrospective data • Review

First-in-man, first-in-class phase I study with the monopolar spindle 1 kinase inhibitor S81694 administered intravenously in adult patients with advanced, metastatic solid tumours. (PubMed, Eur J Cancer) - "S81694 can be administered safely as a single agent in adults with solid tumours on days 1,8,15 of a 28-day cycle up to a dose of 135 mg/m/week without reaching MTD. The RP2D was not defined due to the prioritization of the use of S81694 in combination with cytotoxic agents, based on emerging preclinical data."

Journal • P1 data • Fatigue • Gastrointestinal Cancer • Genito-urinary Cancer • Hematological Disorders • Hepatocellular Cancer • Hypertension • Neutropenia • Oncology • Renal Cell Carcinoma • Solid Tumor

Efficacy of amisulpride for depressive symptoms in individuals with mental disorders: A systematic review and meta-analysis. (PubMed, Hum Psychopharmacol) - "Treatment with amisulpride could be a valid choice for selected individuals with dysthymia or depressive symptoms in the context of schizophrenia. More studies on the efficacy and tolerability of amisulpride are needed to draw firm conclusions on its potential benefits in other psychiatric disorders."

Journal • Retrospective data • Review • CNS Disorders • Depression • Major Depressive Disorder • Mental Retardation • Psychiatry • Schizophrenia

Tricyclic antidepressants versus 'active placebo', placebo or no intervention for adults with major depressive disorder: a protocol for a systematic review with meta-analysis and Trial Sequential Analysis. (PubMed, Syst Rev) - "Tricyclic antidepressants are recommended by clinical guidelines and frequently used worldwide in the treatment of major depressive disorder. There is a need for a thorough systematic review to provide the necessary background for weighing the benefits against the harms. This review will ultimately inform best practice in the treatment of major depressive disorder."

Journal • Retrospective data • Review • CNS Disorders • Depression • Major Depressive Disorder • Mental Retardation • Mood Disorders • Psychiatry

Beneficial and harmful effects of antidepressants versus placebo, 'active placebo', or no intervention for adults with major depressive disorder: a protocol for a systematic review of published and unpublished data with meta-analyses and trial sequential analyses. (PubMed, Syst Rev) - "As antidepressants are commonly used to treat major depressive disorder in adults, a systematic review evaluating their beneficial and harmful effects is urgently needed. This review will inform best practice in treatment and clinical research of this highly prevalent and burdensome disorder."

Clinical • Journal • Review • CNS Disorders • Depression • Major Depressive Disorder • Mental Retardation • Mood Disorders • Psychiatry • Suicidal Ideation

S 81694 Plus Paclitaxel in Metastatic Breast Cancer (clinicaltrials.gov) - P1/2; N=22; Completed; Sponsor: Institut de Recherches Internationales Servier; Active, not recruiting ➔ Completed

Clinical • Combination therapy • Trial completion • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

Thuwalallenes A-E and Thuwalenynes A-C: New C Acetogenins with Anti-Inflammatory Activity from a Saudi Arabian Red Sea Laurencia sp. (PubMed, Mar Drugs) - "Thuwalallenes A-E (1-3, 5 and 8) and thuwalenynes A-C (4, 6, 7), new C acetogenins featuring uncommon ring systems, along with cis-maneonene D (9), thyrsiferol (10) and 23-acetyl-thyrsiferol (11) were isolated from the organic extract of a population of the red alga Laurencia sp., collected at Rose Reef off the village of Thuwal in the Red Sea waters of the Kingdom of Saudi Arabia...Besides compound 4 that did not exhibit any activity, all other tested metabolites inhibited NO production from activated macrophages. Among them, thyrsiferol (10) and 23-acetylthyrsiferol (11) displayed activity with IC values in the low nM scale without cytotoxicity."

Journal

S 81694 Plus Paclitaxel in Metastatic Breast Cancer (clinicaltrials.gov) - P1/2; N=22; Active, not recruiting; Sponsor: Institut de Recherches Internationales Servier; Recruiting ➔ Active, not recruiting; N=117 ➔ 22; Trial completion date: Mar 2023 ➔ Mar 2020; Trial primary completion date: Mar 2023 ➔ Mar 2020

Clinical • Combination therapy • Enrollment change • Enrollment closed • Trial completion date • Trial primary completion date

Preclinical Activity of the MPS1 Inhibitor S81694 in Acute Lymphoblastic Leukemia (ALL) (ASH 2019) - "A small molecule Mps1i (S81694) was tested alone (0 to 1000nM) or in combination with imatinib, dasatinib, nilotinib and ponatinib in BCR-ABL1+ ALL cell lines. Mps1i S81694 yields significant preclinical activity in T-and B-cell ALL including BCR-ABL1+ models. Interestingly S81694 was efficacious in a TKI resistant cell line."

Preclinical • ABL1 • MPS1

S 81694 Plus Paclitaxel in Metastatic Breast Cancer (clinicaltrials.gov) - P1/2; N=117; Recruiting; Sponsor: Institut de Recherches Internationales Servier; Trial completion date: Jun 2022 ➔ Mar 2023; Trial primary completion date: Jun 2021 ➔ Mar 2023

Clinical • Combination therapy • Trial completion date • Trial primary completion date